Macular edema. A complication of diabetic retinopathy

Ferris, Frederick L.; Patz, Arnall

doi:10.1016/0039-6257(84)90227-3

Cited by 302 publications

(155 citation statements)

References 32 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…However, the clinical assessment of macular oedema, using contact lens or Volk lens fundus biomicroscopy, relies upon the subjective recognition of retinal thickening [46±47]. The differentiation of thickened retina from normal between-subject variation is difficult [48] and the detection of change in retinal thickening over time is problematic. Alternative means of detecting and monitoring DMO are necessary to improve the clinical management of this sight threatening complication of diabetes and for the evaluation of therapeutic protocols [49].…”

Section: Discussionmentioning

confidence: 99%

Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema

et al. 1998

View full text Add to dashboard Cite

Perimetry comprises the assessment of visual sensitivity of retinal locations eccentric from the fovea. Short-wavelength automated perimetry employs a blue stimulus in order to preferentially stimulate the short-wavelength sensitive (SWS) pathway and a high luminance yellow background to saturate both the medium-and long-wavelength sensitive pathways and to simultaneously suppress rod activity [1]. Numerous studies have shown that short-wavelength perimetry detects glaucomatous visual field damage at an earlier stage in the disease process than conventional white-on-white perimetry [2±11]. Diabetologia (1998) Summary The aim of the study was to compare the sensitivity of short-wavelength and conventional automated static threshold perimetry for the psychophysical detection of abnormality in patients with clinically significant diabetic macular oedema. The sample comprised 24 patients with clinically significant diabetic macular oedema (mean age 59.75 years, range 45±75 years). One eye of each patient was selected. Exclusion criteria included the presence of lenticular opacity. The sensitivity of the macular visual field of each patient was determined with programme 10±2 of the Humphrey Field Analyser on two occasions, using both short-wavelength and conventional stimulus parameters; the results of the second session were analysed to minimise learning effects. A pointwise horizontal hemifield asymmetry analysis was derived for short-wavelength perimetry (thereby negating the influence of pre-receptoral absorption); the pointwise pattern deviation probability plot was analysed for conventional perimetry. Abnormality was defined as 3 or more contiguous stimulus locations with negative asymmetries (short-wavelength) or reduced sensitivity values (conventional) that resulted in a statistical probability level of p less than 0.05. The fields of 8 patients were abnormal as assessed by conventional perimetry while all were classified as abnormal using short-wavelength perimetry. In the 8 patients who exhibited both abnormal conventional and abnormal short-wavelength perimetry results, the extent of field loss was generally greater using short-wavelength perimetry. The position of the localised field loss (i. e. as distinct from field loss that was generalised across the visual field) assessed by short-wavelength perimetry corresponded with the clinical mapping of the area of diabetic macular oedema but the extent of this loss was generally greater than that suggested by clinical assessment. Short-wavelength automated perimetry offers improved sensitivity for the psychophysical detection of clinically significant diabetic macular oedema. [Diabetologia (1998) 41: 918±928]

show abstract

Section: Discussionmentioning

confidence: 99%

Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema

et al. 1998

View full text Add to dashboard Cite

show abstract

“…The Wisconsin Epidemiologic Study of Diabetic Retinopathy showed that the ten-year rate of developing DME in the US was 20.1% among Type I diabetics, 25.4% among insulin-dependent Type II diabetics, and 13.9% for non-insulin dependent Type II diabetics [2]. Nearly half of those developing DME will lose two or more lines of visual acuity within two years [3].…”

Section: Introductionmentioning

confidence: 99%

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy

Hussain

Ciulla

2016

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…Diabetic macular edema (DME) is a common complication of diabetic retinopathy and the leading cause for visual impairment in the working population in industrialized countries (Ferris & Patz 1984;Chew et al 1996;Moss et al 1998). DME is defined as thickening located within two disc diameters of the centre of the macula.…”

Section: Introductionmentioning

confidence: 99%

Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment

et al. 2013

View full text Add to dashboard Cite

ABSTRACT.Purpose: To evaluate macular morphology and function in diabetic macular edema (DME) over the course of intravitreal anti-vascular endothelial growth factor (VEGF) treatment with Ranibizumab.Methods: A consecutive series of 39 study eyes with centre-involving DME were included in this study. In all subjects, best-corrected visual acuity (BCVA) according ETDRS protocol, fluorescein angiography (FA), microperimetric macular sensitivity (MP) and Spectral Domain optical coherence tomography (SD-OCT) cross-sectional scans were obtained before treatment and after 3 monthly applied intravitreal Ranibizumab injections. Six different morphological qualities [IS ⁄ OS layer integrity, outer nuclear layer (ONL) cysts, ONL cyst size, inner nuclear layer (INL) cysts, blocking phenomenon and subretinal fluid] were graded of each cross-sectional OCT scan before and over the course of treatment by two experienced graders. Correlation analyses between functional and morphological parameters were obtained. Conclusions: ONL cysts and their size as morphological parameters correlate with retinal function measured with BCVA and microperimetry before and over the course of anti-VEGF therapy with Ranibizumab in patients with DME. Results:

show abstract

Macular edema. A complication of diabetic retinopathy

Cited by 302 publications

References 32 publications

Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema

Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy

Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment

Contact Info

Product

Resources

About